Secukinumab: a new treatment option for psoriatic arthritis

Mease, P. and McInnes, I. B. (2016) Secukinumab: a new treatment option for psoriatic arthritis. Rheumatology and Therapy, 3(1), pp. 5-29. (doi:10.1007/s40744-016-0031-5) (PMID:27747518) (PMCID:PMC4999581)

[img]
Preview
Text
130662.pdf - Published Version
Available under License Creative Commons Attribution.

1MB

Abstract

Introduction: Psoriatic arthritis (PsA) is an immune-mediated chronic inflammatory arthropathy associated with impaired physical function and reduced quality of life. Biologic therapies that target tumor necrosis factor (anti-TNF) have significantly improved clinical outcomes. Partial, non- and transient responses remain common comprising significant unmet clinical need. New therapies with novel modes of action are urgently required. Objectives: The interleukin (IL)-17 pathway has recently been attributed a critical role in the pathogenesis of spondyloarthritides. Herein, we review data from clinical studies with secukinumab, a novel fully human IgG1κ anti-IL-17A monoclonal antibody (mAb), in patients with active PsA. Results: Across two pivotal phase 3 studies, secukinumab provided significant and sustained reductions in the signs and symptoms of PsA, inhibition of radiographic progression, and improved patient-reported outcomes and measures of quality of life. The primary efficacy endpoint, a ≥20% improvement from baseline according to the American College of Rheumatology 20 (ACR20) response at Week 24, was significantly higher in patients treated with secukinumab compared with placebo, with improvements sustained through at least 52 weeks. Clinical benefits were seen with secukinumab regardless of concomitant methotrexate treatment and in patients who were either anti-TNF-naïve or who were inadequate responders to anti-TNF therapy. Secukinumab was well-tolerated, with a safety profile consistent with that previously reported in psoriasis trials. The most common adverse events were nasopharyngitis, upper respiratory tract infections, and headache. Conclusion: Secukinumab offers an effective new addition to the available treatment options for PsA. Regulatory submissions have been filed worldwide, with the first approvals recently obtained in Japan and Europe. Future studies are required to define the optimal timing and strategic use of this novel treatment modality.

Item Type:Articles
Additional Information:Iain B. McInnes acknowledges support from Arthritis Research UK for the ongoing rheumatology program in University of Glasgow
Status:Published
Refereed:Yes
Glasgow Author(s) Enlighten ID:McInnes, Professor Iain
Authors: Mease, P., and McInnes, I. B.
College/School:College of Medical Veterinary and Life Sciences > Institute of Infection Immunity and Inflammation
Journal Name:Rheumatology and Therapy
Publisher:Springer
ISSN:2198-6576
ISSN (Online):2198-6584
Published Online:23 April 2016
Copyright Holders:Copyright © 2016 The Authors
First Published:First published in Rheumatology and Therapy 3(1):5-29
Publisher Policy:Reproduced under a Creative Commons License
Related URLs:

University Staff: Request a correction | Enlighten Editors: Update this record